Value
8.7/10data confidence 83%| Component | Sub-score |
|---|---|
| P/S | 10.0 |
| EV/EBITDA | 8.4 |
| Fwd P/E | 10.0 |
| PEG | 10.0 |
| Analyst target | 5.0 |
- ▸Forward P/E: 1.5x
- ▸PEG: 0.01
- ▸Attractively valued
BHC · Why this verdict
Why Bausch Health Companies (BHC) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score6.5/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Bausch Health offers deep statistical value — a 1.2x forward P/E and approximately 7-to-1 risk/reward in the buyer's favor — but is in a confirmed technical downtrend with a death cross in place, mixed earnings execution, and extreme revenue concentration in a single product; the asymmetric setup favors patience for a catalyst rather than active accumulation into the breakdown.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Despite a GAAP net loss, the business converts revenues into positive free cash flow at an 11% margin with a 60.3% FCF yield, suggesting the underlying cash economics are meaningfully healthier than the accounting income statement alone implies. Quality breakdown | FCF margin remains above 8% and FCF yield stays above 40% across the next two reported periods, confirming the cash-generation thesis. | →Stable |
| CounterPositive free cash flow sustained during a period of GAAP losses can reflect deferred investment or working capital release rather than structural cash generation; if those levers reverse, the FCF cushion could erode quickly. | ||
With a single product representing 85% of revenues, the business carries concentrated binary risk — any adverse regulatory, competitive, or patent development affecting that franchise could simultaneously impair the overwhelming majority of the revenue base. Bear case | Over 12 months, the leading product's revenue contribution declines below 75% as other segments grow, reducing concentration risk. | ↓Deteriorating |
| CounterA concentrated product mix can be a feature as much as a risk if that product holds pricing power and market share; concentration does not predetermine negative outcomes and may amplify any upside as well. | ||
At a forward P/E of 1.2x and a near-zero PEG, the stock screens as deeply undervalued relative to earnings power, and analyst consensus implies roughly 29% upside to the $6.44 target against a far more modest downside — a risk/reward of approximately 7-to-1 in favor of the buyer. Price targets | Analyst consensus price target holds above $6.00 and the stock closes above $6.44 within 12 months as the valuation gap narrows. | ↓Deteriorating |
| CounterExtreme cheapness may reflect a genuine value trap; consecutive earnings misses and the death cross suggest the market is pricing in further deterioration that ratio-based valuation screens cannot fully capture. | ||
A death cross is confirmed, the stock trades below all key moving averages with the 200-day slope running at -3.4% over 30 days, and RSI sits at 36 — a pattern consistent with sustained selling pressure rather than a temporary dislocation that self-corrects quickly. Momentum breakdown | If this technical breakdown reverses, the stock should cross above its 200-day moving average and sustain an RSI above 50 for at least 4 consecutive weeks. | ↑Improving |
| CounterAt an RSI of 36 with a 1.2x forward P/E, the stock is deeply oversold on both a technical and fundamental basis; any positive earnings catalyst or strategic announcement could trigger a sharp mean-reversion rally. | ||
Despite a GAAP net loss, the business converts revenues into positive free cash flow at an 11% margin with a 60.3% FCF yield, suggesting the underlying cash economics are meaningfully healthier than the accounting income statement alone implies.
→StableQuality breakdown
- Expectation
- FCF margin remains above 8% and FCF yield stays above 40% across the next two reported periods, confirming the cash-generation thesis.
CounterPositive free cash flow sustained during a period of GAAP losses can reflect deferred investment or working capital release rather than structural cash generation; if those levers reverse, the FCF cushion could erode quickly.
With a single product representing 85% of revenues, the business carries concentrated binary risk — any adverse regulatory, competitive, or patent development affecting that franchise could simultaneously impair the overwhelming majority of the revenue base.
↓DeterioratingBear case
- Expectation
- Over 12 months, the leading product's revenue contribution declines below 75% as other segments grow, reducing concentration risk.
CounterA concentrated product mix can be a feature as much as a risk if that product holds pricing power and market share; concentration does not predetermine negative outcomes and may amplify any upside as well.
At a forward P/E of 1.2x and a near-zero PEG, the stock screens as deeply undervalued relative to earnings power, and analyst consensus implies roughly 29% upside to the $6.44 target against a far more modest downside — a risk/reward of approximately 7-to-1 in favor of the buyer.
↓DeterioratingPrice targets
- Expectation
- Analyst consensus price target holds above $6.00 and the stock closes above $6.44 within 12 months as the valuation gap narrows.
CounterExtreme cheapness may reflect a genuine value trap; consecutive earnings misses and the death cross suggest the market is pricing in further deterioration that ratio-based valuation screens cannot fully capture.
A death cross is confirmed, the stock trades below all key moving averages with the 200-day slope running at -3.4% over 30 days, and RSI sits at 36 — a pattern consistent with sustained selling pressure rather than a temporary dislocation that self-corrects quickly.
↑ImprovingMomentum breakdown
- Expectation
- If this technical breakdown reverses, the stock should cross above its 200-day moving average and sustain an RSI above 50 for at least 4 consecutive weeks.
CounterAt an RSI of 36 with a 1.2x forward P/E, the stock is deeply oversold on both a technical and fundamental basis; any positive earnings catalyst or strategic announcement could trigger a sharp mean-reversion rally.
Per-dimension breakdown
Quality
6.4/10data confidence 100%| Component | Sub-score |
|---|---|
| ROA | 4.4 |
| Gross margin | 10.0 |
| Op margin | 10.0 |
| Net margin | 0.0 |
| Current ratio | 5.3 |
| FCF quality | 6.6 |
| Moat | 7.0 |
| Rule of 40 | 5.5 |
| Piotroski F | 8.9 |
- ▸FCF-positive despite GAAP loss (FCF margin 13%, FCF yield 60.5%)
- ▸Strong Piotroski F-Score: 8/9
Growth
7.8/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 5.7 |
| EPS growth | 10.0 |
Momentum
5.4/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.4 |
| MACD | 7.6 |
| OBV | 6.9 |
| MA position | 8.0 |
| Volume | 0.0 |
- ▸Overbought (RSI 73)
- ▸Above 200-MA but MA slope flat
Sentiment
5.7/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 7.1 |
| erm sentiment | 5.0 |
Insider
6.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 6.9 |
| notable moves | 7.0 |
- ▸Insider selling (low materiality) — $132,796 (0.006% of mkt cap)
Peer rank
5.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 9.2 |
| quality rank | 2.4 |
| growth rank | 6.4 |
Technical
3.5/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 2.7 |
| support resistance | 2.7 |
| 52w position | 5.0 |
Risk (lower is worse)
5.5/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 8.7 |
| days to cover | 8.8 |
| volatility | 0.0 |
| put call | 5.5 |
| implied vol | 0.0 |
| beta | 10.0 |
- ▸High IV: 96%
- ▸Concentration risks: 2 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
5.9/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 6.9 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Maintain position. Not compelling to add more.
Engine technical detail
verdict_path:
L4:PATH_F_HOLDPassed (7)
- MOMENTUM:5.4>=4.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:75d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:0.0<1.5@spot
Warning (2)
- MOMENTUM:5.4<5.5 (soft — BUY_NOW allowed but watch)
- DEATH_CROSS:momentum=5.4>=5.0 recovering
Reward-to-Risk
0.02
Upside
+0.2%
Downside
15.0%
Sizing output
AVOID
SetupRecovery — Death cross but MACD improving, RSI 73
EdgeNo clear edge — No clear edge identified
SuitabilityAggressive — MCap $2.4B<$5B
Investment implication
None of the engine's positive-conviction paths (C-quality, D-momentum) triggered — the F-path HOLD reflects balanced signals. Strongest-cleared gate: MOMENTUM:5.4>=4.5. Top dim: Value at 8.7; weakest: Technical at 3.5. No conviction either direction.
The strongest dimensions are Value at 8.7, Growth at 7.8, and Quality at 6.4; the weakest are Technical at 3.5, Momentum at 5.4, and Risk (lower is worse) at 5.5. The V9 engine flagged 1 failed gate with 2 warnings, producing an asymmetric reward-to-risk of 0.02 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Deep Value Asymmetric Upside
Trip ifAnalyst consensus price target falls below $5.50, reducing implied upside to less than 10%.
- P2Product Concentration Binary Risk
Trip ifLeading product revenue contribution falls below 70% of total revenue for 2 consecutive reported periods.
- P3Confirmed Downtrend Limits Near Term Recovery
Trip ifStock closes above its 200-day moving average and RSI exceeds 50 for 4 consecutive weeks.
- P4Fcf Generation Cushions Gaap Losses
Trip ifFCF margin falls below 5% for 2 consecutive reported quarters.